|130.18|| 0.00 / 0.00%|
Intercept Pharmaceuticals, Inc. is a development stage biopharmaceutical company. It focuses on the discovering, developing and commercializing of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. It develops obeticholic acid, a bile acid analog that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase II clinical trial for the treatment of alcoholic hepatitis; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea. Intercept Pharmaceuticals was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
|Mark E. Pruzanski||President, Chief Executive Officer & Director|
|Sandip Kapadia||Chief Financial Officer|
|David A. Shapiro||Chief Medical Officer & Executive VP-Development|
|Luciano Adorini||Chief Scientific Officer|
|Rachel L. McMinn||Chief Business & Strategy Officer|